Sareum TYK2/JAK1 inhibitors!27 Jun 2019 12:57
Couple of key points!
The Company generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
These potent and selective small molecules target important mechanisms in cancer and autoimmune diseases and provide potentially high-value opportunities to develop new therapies for patients:-
1. TYK2 SDC-1801 for RA In Preclinical Development for First in Human Clinical Trials.
2. TYK2 SDC-1802 for Cancer In Preclinical Development for First in Human Clinical Trials.
A. Members of the JAK family are the targets of several marketed and clinical-stage drugs for cancer and autoimmune diseases, although there are currently no marketed products specifically targeting TYK2.
B. Currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies with a maximum tolerated dose (MTD) yet to be reached.
C. Candidate molecule, SDC-1801, demonstrated high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3), compelling activity in disease models of psoriasis and rheumatoid arthritis, the potential for once-daily oral dosing and a good early safety profile.
D. Strong candidate that exhibits potentially best-in-class features.
Work in Progress!
“Data arising from some of this work are being prepared for submission to a peer-reviewed publication and a conference presentation.”
“Multiple dose-finding studies are now ongoing to identify doses to use in specific toxicology studies, which are intended to form part of the applications for initial human trials. Additional research to refine the clinical plans, including prioritisation of potential target indications, is continuing.”
“In addition, the Company has been exploring robust manufacturing routes to produce each candidate for preclinical and clinical studies. Such a route has been developed for SDC-1801 and activities continue to confirm a route of synthesis for SDC-1802.”
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
https://link.springer.com/article/10.1007/s40259-019-00333-w
Sign In
Follow the stocks
